Table 1.
miRNAs regulate epigenetic modifications in cancer.
| Cancer | miRNA | Expression | Epi Regulator | Epi Modification | Epi Target | Ref |
|---|---|---|---|---|---|---|
| Acquired resistance of breast cancer | miR-29a miR-29b-3p |
High | DNMT-3a | DNA Methylation | global DNA methylation | [36] |
| miR-132 | High | MeCP2 | DNA Methylation | global DNA methylation | ||
| Acute myeloid leukaemia | miR-29b-3p | High | DNMT-3a/DNMT-3b/DNMT-1 | DNA Methylation | ESR1/cyclin-dependent kinase inhibitor 2B | [37] |
| Bladder transitional cell carcinoma | miR-101-3p | Low | EZH2 | H3K27me3 | - | [38] |
| Breast cancer | miR-10a | Low | - | H3K27me3/DNA Methylation | HOXD4 | [39] |
| miR-29c miR-26b miR-148b |
High | DNMT-3b | DNA Methylation | CEACAM6/CST6/SCNN1A | [40] | |
| miR-148a | High | DNMT-1 | DNA Methylation | miR-148a | [41] | |
| miR-152 | High | DNMT-1 | DNA Methylation | miR-152 | ||
| Breast/Prostate | miR-101-3p | High | EZH2 | H3K27me3 | miR-101 | [42] |
| Colorectal cancer | miR-143 | Low | DNMT-3a | DNA Methylation | - | [43] |
| miR-342 | High | DNMT-1 | DNA Methylation | ADAM23/Hint1/RASSF1A/RECK | [44] | |
| Cutaneous melanoma | miR-29a-3p | High | DNMT-3a/DNMT-3b | DNA Methylation | RASSF1A/TFPI-2/RAR-/SOCS/GATA4 | [45] |
| Endometrial cancer | miR-152 | Low | DNMT-1 | DNA Methylation | - | [46] |
| Gastric cancer | miR-148a | High | DNMT-1 | DNA Methylation | miR-148a | [47] |
| Glioblastoma | miR-101-3p | Low | EZH2 | H3K27me3 | - | [48] |
| miR-152 | High | DNMT-1 | DNA Methylation | miR-152 | [49] | |
| Glioma | miR-185 | High | DNMT-1 | DNA Methylation | ANKDD1A/GAD1/HIST1H3E/PCDHA8/PCDHA13/PHOX2B/SIX3/SST | [50] |
| Hepatitis B virus (HBV)-related hepatocellular carcinoma | miR-101-3p | High | DNMT-3a | DNA Methylation | RASSF1/PRDM2/GSTP1/RUNX3 | [51] |
| Hepatocellular carcinoma | miR-200a | High | HDAC4 | H3ac | miR-200a | [52] |
| miR-125b-5p | High | SUV39H1 | H3K9me3 | Ki67 | [53] | |
| miR-152 | High | DNMT-1 | DNA Methylation | GSTP1/CDH1 | [54] | |
| Hilar cholangiocarcinoma | miR-373 | High | MBD2 | DNA Methylation | MBD2 regulate RASSF1A | [55] |
| High | MBD2 | DNA Methylation | miR-373 | [56] | ||
| Human malignant cholangiocytes | miR-148a miR-152 |
High | DNMT-1 | DNA Methylation | Rassf1a/p16INK4a | [57] |
| Leukaemia and lymphoma cells | miR-19a miR-25 miR-32 miR-92b miR-96 |
High | PRMT5 | DNA Methylation | H3R8/H4R3 | [58] |
| Lung cancer | miR-101-1 | High | EZH2 | H3K27me3 | CDH1 | [59] |
| Melanoma | miR-31 | High | EZH2 | DNA Methylation | miR-31 | [60] |
| Multiple myeloma | miR-29b-3p | Low | DNMT-3a/DNMT-3b | DNA Methylation | - | [61] |
| Non-small-cell lung cancer | miR-29a miR-29b-3p miR-29c |
High | DNMT-3a/DNMT-3b | DNA Methylation | FHIT/WWOX | [62] |
| miR-29b-3p | High | DNMT-1/DNMT-3a/DNMT-3b | DNA Methylation | PTEN | [63] | |
| miR-29b-3p | High | DNMT-3b | DNA Methylation | CADM1/RASSF1/FHIT | [64] | |
| Ovarian cancer | miR-185 miR-152 |
Low | DNMT-1 | DNA Methylation | - | [65] |
| Prostate cancer | miR-34b | High | HDAC1/HDAC2/HDAC4 | H3K4me3 | miR-34b | [66] |
| DNMT-1 | DNA Methylation | |||||
| miR-449a | Low | HDAC1 | Histone Acetylation | - | [67] | |
| miR-101-3p | Low | EZH2 | H3K27me3 | - | [68] | |
| Squamous cell carcinoma | miR-138-5p | High | EZH2 | H3K27me3 | E-cad | [69] |
| T-cell leukaemia | miR-101-3p miR-128 |
Low | EZH2 | H3K27me3 | - | [70] |